Long-Term Outcomes in Stage IIIB Breast Cancer Patients Who Achieved Less Than a Pathological Complete Response (
Autor: IONTA, MARIA TERESA, ATZORI, FRANCESCO, DEIDDA, MARIA CRISTINA, PUSCEDDU, VALERIA, PALMERI, SERGIO, FRAU, BARBARA, MURGIA, MONICA, BARCA, MICHELA, MINERBA, LUIGI, MASSIDDA, BRUNO
Předmět:
Zdroj: Oncologist; Nov2009, Vol. 14 Issue 11, p1051-1060, 10p, 2 Charts, 5 Graphs
Abstrakt: Purpose. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of our study were the longterm DFS and OS rates in homogeneously treated stage IIIB breast cancer patients who failed to achieve a pCR (- tumors had significantly lower 10-year DFS (17.3% versus 46.4%; p = .018) and OS (17.3% versus 70.2%; p = .002) rates. Overall, the triple-negative (TN) group showed only a marginally significantly worse OS rate (p=.048). HER-2 status alone, in the absence of trastuzumab, did not appear to significantly affect outcomes. Conclusions. Our data suggest that, in stage IIIB patients who achieve- status are strong predictors of poor outcomes. After a long follow-up time, HER-2 expression does not appear to significantly affect DFS and OS. TN patients showed a trend toward early recurrence and death. The Oncologist 2009;14:1051-1060 [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: